BioAge Labs, Inc.
NASDAQ:BIOABiotechnology
+$0.47 today
- Market cap
- $179.59M
- Beta
- 0.95
- P/E (TTM)
- -9.7
- EPS (TTM)
- -$2.12
Volume 0.64M
Average 0.46M
BIOA Operating Cash Flow
Cash generated by the company's core business operations during the period.
BioAge Labs, Inc.NASDAQ: BIOA
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow grows, but more slowly than its trailing trend
Q1 FY2026 operating cash flow of $24.05M (cash outflow) rose 38.5% year over year, behind the +66.0% change in trailing-twelve-month operating cash flow. Sequentially, it fell 14.9% from the prior quarter. Over 3 fiscal years it compounded at +31.2% a year.
Context
- Operating cash flow amounted to 907.5% of revenue in FY2025.
- Operating cash flow grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +38.5% toward the trailing-twelve-month pace of +66.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (81.63M) USD
- Year-over-year change
- -58.4%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (81.63M) | -58.4% |
| FY2024 | 2024-12-31 | (51.52M) | -37.9% |
| FY2023 | 2023-12-31 | (37.36M) | -3.3% |
| FY2022 | 2022-12-31 | (36.18M) | — |
Operating Cash Flow vs competitors
How BIOA compares with its peers on the latest reported figures
- Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +66.0% is the highest of 9, against a peer median of -27.6%.
- Operating cash flow amounts to 856.0% of revenue for BIOA, versus a peer median of 20.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $147.86M USD | +17.2% | +3.0% | — | |
| LTM Mar 2026 | $142.84M USD | +50.3% | +41.4% | — | |
| LTM Mar 2026 | $140.5M USD | -32.5% | -2.3% | 363.1% | |
| LTM Mar 2026 | $109.23M USD | -44.6% | -12.2% | — | |
| LTM Mar 2026 | $101.54M USD | +2.2% | +13.9% | 5037.0% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $88.31M USD | +66.0% | +31.2% | 856.0% |
| LTM Mar 2026 | CA$70.22M CAD | -57.6% | -45.8% | 22.5% | |
| LTM Mar 2026 | $17.38M USD | — | -79.1% | 12.9% | |
| LTM Mar 2026 | CA$13.51M CAD | -184.4% | -51.1% | 4.3% | |
| LTM Mar 2026 | $7.7M USD | -22.7% | -31.9% | 18.4% | |
| Peer median (excluding BIOA) | — | -27.6% | -12.2% | 20.5% | |
Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
BioAge Labs, Inc.
NASDAQ:BIOA
Intrinsic Alpha fair value
Locked
Current Price
$4.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.